Intrinsic value of Icon - ICLR

Previous Close

$115.01

  Intrinsic Value

$91.13

stock screener

  Rating & Target

sell

-21%

Previous close

$115.01

 
Intrinsic value

$91.13

 
Up/down potential

-21%

 
Rating

sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ICLR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of Icon (ICLR) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  5.78
  4.80
  4.82
  4.84
  4.85
  4.87
  4.88
  4.89
  4.90
  4.91
  4.92
  4.93
  4.94
  4.94
  4.95
  4.95
  4.96
  4.96
  4.97
  4.97
  4.97
  4.98
  4.98
  4.98
  4.98
  4.98
  4.99
  4.99
  4.99
  4.99
  4.99
Revenue, $m
  1,666
  1,746
  1,830
  1,919
  2,012
  2,110
  2,213
  2,321
  2,435
  2,555
  2,680
  2,812
  2,951
  3,097
  3,250
  3,411
  3,581
  3,758
  3,945
  4,141
  4,347
  4,563
  4,790
  5,029
  5,280
  5,543
  5,819
  6,109
  6,414
  6,734
  7,070
Variable operating expenses, $m
 
  1,186
  1,240
  1,297
  1,357
  1,420
  1,487
  1,556
  1,630
  1,707
  1,788
  1,811
  1,901
  1,995
  2,093
  2,197
  2,306
  2,420
  2,541
  2,667
  2,800
  2,939
  3,085
  3,239
  3,400
  3,570
  3,748
  3,935
  4,131
  4,337
  4,553
Fixed operating expenses, $m
 
  232
  237
  243
  249
  256
  262
  269
  275
  282
  289
  297
  304
  312
  319
  327
  335
  344
  352
  361
  370
  380
  389
  399
  409
  419
  429
  440
  451
  462
  474
Total operating expenses, $m
  1,355
  1,418
  1,477
  1,540
  1,606
  1,676
  1,749
  1,825
  1,905
  1,989
  2,077
  2,108
  2,205
  2,307
  2,412
  2,524
  2,641
  2,764
  2,893
  3,028
  3,170
  3,319
  3,474
  3,638
  3,809
  3,989
  4,177
  4,375
  4,582
  4,799
  5,027
Operating income, $m
  312
  328
  352
  378
  405
  434
  464
  496
  530
  565
  603
  705
  747
  791
  838
  887
  939
  994
  1,052
  1,113
  1,177
  1,245
  1,316
  1,391
  1,471
  1,554
  1,642
  1,735
  1,832
  1,935
  2,043
EBITDA, $m
  371
  406
  431
  457
  485
  515
  546
  579
  614
  650
  689
  730
  774
  819
  867
  918
  972
  1,028
  1,088
  1,151
  1,217
  1,286
  1,360
  1,437
  1,519
  1,605
  1,695
  1,790
  1,891
  1,996
  2,107
Interest expense (income), $m
  14
  14
  16
  17
  19
  21
  23
  26
  28
  30
  33
  35
  38
  41
  44
  47
  51
  54
  58
  62
  66
  71
  75
  80
  85
  90
  96
  102
  108
  114
  121
Earnings before tax, $m
  300
  314
  337
  361
  386
  412
  441
  470
  502
  535
  570
  669
  708
  750
  794
  840
  888
  940
  994
  1,051
  1,111
  1,174
  1,241
  1,311
  1,386
  1,464
  1,546
  1,633
  1,724
  1,820
  1,922
Tax expense, $m
  38
  85
  91
  97
  104
  111
  119
  127
  136
  145
  154
  181
  191
  202
  214
  227
  240
  254
  268
  284
  300
  317
  335
  354
  374
  395
  417
  441
  466
  491
  519
Net income, $m
  262
  229
  246
  263
  282
  301
  322
  343
  366
  391
  416
  489
  517
  547
  579
  613
  648
  686
  725
  767
  811
  857
  906
  957
  1,011
  1,069
  1,129
  1,192
  1,259
  1,329
  1,403

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  261
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,826
  1,639
  1,718
  1,802
  1,889
  1,981
  2,078
  2,179
  2,286
  2,399
  2,517
  2,641
  2,771
  2,908
  3,052
  3,203
  3,362
  3,529
  3,704
  3,888
  4,082
  4,285
  4,498
  4,722
  4,957
  5,204
  5,464
  5,736
  6,023
  6,323
  6,639
Adjusted assets (=assets-cash), $m
  1,565
  1,639
  1,718
  1,802
  1,889
  1,981
  2,078
  2,179
  2,286
  2,399
  2,517
  2,641
  2,771
  2,908
  3,052
  3,203
  3,362
  3,529
  3,704
  3,888
  4,082
  4,285
  4,498
  4,722
  4,957
  5,204
  5,464
  5,736
  6,023
  6,323
  6,639
Revenue / Adjusted assets
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
  1.065
Average production assets, $m
  209
  218
  229
  240
  251
  264
  277
  290
  304
  319
  335
  352
  369
  387
  406
  426
  448
  470
  493
  518
  543
  570
  599
  629
  660
  693
  727
  764
  802
  842
  884
Working capital, $m
  464
  213
  223
  234
  245
  257
  270
  283
  297
  312
  327
  343
  360
  378
  397
  416
  437
  459
  481
  505
  530
  557
  584
  614
  644
  676
  710
  745
  783
  822
  863
Total debt, $m
  349
  391
  435
  482
  532
  583
  638
  695
  755
  818
  885
  955
  1,028
  1,105
  1,186
  1,271
  1,361
  1,455
  1,553
  1,657
  1,766
  1,880
  2,000
  2,127
  2,259
  2,398
  2,544
  2,698
  2,859
  3,028
  3,206
Total liabilities, $m
  881
  923
  967
  1,014
  1,064
  1,115
  1,170
  1,227
  1,287
  1,350
  1,417
  1,487
  1,560
  1,637
  1,718
  1,803
  1,893
  1,987
  2,085
  2,189
  2,298
  2,412
  2,532
  2,659
  2,791
  2,930
  3,076
  3,230
  3,391
  3,560
  3,738
Total equity, $m
  945
  716
  751
  787
  825
  866
  908
  952
  999
  1,048
  1,100
  1,154
  1,211
  1,271
  1,334
  1,400
  1,469
  1,542
  1,619
  1,699
  1,784
  1,872
  1,966
  2,064
  2,166
  2,274
  2,388
  2,507
  2,632
  2,763
  2,901
Total liabilities and equity, $m
  1,826
  1,639
  1,718
  1,801
  1,889
  1,981
  2,078
  2,179
  2,286
  2,398
  2,517
  2,641
  2,771
  2,908
  3,052
  3,203
  3,362
  3,529
  3,704
  3,888
  4,082
  4,284
  4,498
  4,723
  4,957
  5,204
  5,464
  5,737
  6,023
  6,323
  6,639
Debt-to-equity ratio
  0.369
  0.550
  0.580
  0.610
  0.640
  0.670
  0.700
  0.730
  0.760
  0.780
  0.800
  0.830
  0.850
  0.870
  0.890
  0.910
  0.930
  0.940
  0.960
  0.980
  0.990
  1.000
  1.020
  1.030
  1.040
  1.050
  1.070
  1.080
  1.090
  1.100
  1.100
Adjusted equity ratio
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437
  0.437

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  262
  229
  246
  263
  282
  301
  322
  343
  366
  391
  416
  489
  517
  547
  579
  613
  648
  686
  725
  767
  811
  857
  906
  957
  1,011
  1,069
  1,129
  1,192
  1,259
  1,329
  1,403
Depreciation, amort., depletion, $m
  59
  78
  78
  79
  80
  81
  82
  83
  84
  85
  86
  26
  27
  28
  30
  31
  33
  34
  36
  38
  40
  42
  44
  46
  48
  51
  53
  56
  59
  61
  65
Funds from operations, $m
  156
  307
  324
  342
  362
  382
  403
  426
  450
  476
  502
  514
  544
  576
  609
  644
  681
  720
  761
  805
  851
  899
  950
  1,003
  1,060
  1,119
  1,182
  1,248
  1,317
  1,390
  1,467
Change in working capital, $m
  -103
  10
  10
  11
  11
  12
  13
  13
  14
  15
  15
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  28
  29
  31
  32
  34
  35
  37
  39
  41
Cash from operations, $m
  259
  297
  314
  332
  350
  370
  391
  413
  436
  461
  487
  498
  527
  558
  590
  624
  660
  698
  739
  781
  825
  872
  922
  974
  1,029
  1,087
  1,148
  1,212
  1,280
  1,351
  1,426
Maintenance CAPEX, $m
  0
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -26
  -27
  -28
  -30
  -31
  -33
  -34
  -36
  -38
  -40
  -42
  -44
  -46
  -48
  -51
  -53
  -56
  -59
  -61
New CAPEX, $m
  -43
  -10
  -11
  -11
  -12
  -12
  -13
  -14
  -14
  -15
  -16
  -17
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -25
  -26
  -27
  -28
  -30
  -31
  -33
  -35
  -36
  -38
  -40
  -42
Cash from investing activities, $m
  -75
  -25
  -27
  -28
  -30
  -30
  -32
  -34
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -50
  -52
  -55
  -57
  -61
  -64
  -67
  -70
  -74
  -77
  -81
  -86
  -89
  -94
  -99
  -103
Free cash flow, $m
  184
  272
  287
  304
  321
  339
  359
  379
  401
  424
  448
  457
  484
  513
  543
  575
  608
  644
  681
  720
  762
  806
  852
  901
  952
  1,006
  1,063
  1,123
  1,186
  1,253
  1,323
Issuance/(repayment) of debt, $m
  0
  42
  44
  47
  49
  52
  54
  57
  60
  63
  66
  70
  73
  77
  81
  85
  89
  94
  99
  104
  109
  114
  120
  126
  132
  139
  146
  153
  161
  169
  178
Issuance/(repurchase) of shares, $m
  -100
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -94
  42
  44
  47
  49
  52
  54
  57
  60
  63
  66
  70
  73
  77
  81
  85
  89
  94
  99
  104
  109
  114
  120
  126
  132
  139
  146
  153
  161
  169
  178
Total cash flow (excl. dividends), $m
  89
  314
  332
  351
  370
  391
  413
  437
  461
  487
  515
  527
  558
  590
  624
  660
  698
  738
  780
  824
  871
  920
  972
  1,027
  1,084
  1,145
  1,209
  1,276
  1,347
  1,422
  1,501
Retained Cash Flow (-), $m
  -182
  -32
  -35
  -36
  -38
  -40
  -42
  -44
  -47
  -49
  -52
  -54
  -57
  -60
  -63
  -66
  -69
  -73
  -77
  -80
  -85
  -89
  -93
  -98
  -103
  -108
  -113
  -119
  -125
  -131
  -138
Prev. year cash balance distribution, $m
 
  261
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  543
  297
  314
  332
  351
  371
  392
  414
  438
  463
  473
  501
  530
  561
  594
  628
  665
  703
  744
  786
  831
  879
  929
  982
  1,037
  1,096
  1,157
  1,222
  1,291
  1,363
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  520
  272
  273
  273
  272
  269
  265
  259
  252
  243
  224
  214
  201
  188
  174
  160
  145
  129
  114
  100
  86
  73
  61
  50
  40
  32
  25
  19
  14
  10
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

FINANCIAL RATIOS  of  Icon (ICLR)

Valuation Ratios
P/E Ratio 23.9
Price to Sales 3.8
Price to Book 6.6
Price to Tangible Book
Price to Cash Flow 24.2
Price to Free Cash Flow 29
Growth Rates
Sales Growth Rate 5.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -14%
Cap. Spend. - 3 Yr. Gr. Rate 8.2%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 36.9%
Total Debt to Equity 36.9%
Interest Coverage 22
Management Effectiveness
Return On Assets 15.5%
Ret/ On Assets - 3 Yr. Avg. 14%
Return On Total Capital 21.8%
Ret/ On T. Cap. - 3 Yr. Avg. 21.2%
Return On Equity 30.7%
Return On Equity - 3 Yr. Avg. 25.7%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 42.3%
Gross Margin - 3 Yr. Avg. 41.5%
EBITDA Margin 22.4%
EBITDA Margin - 3 Yr. Avg. 20.3%
Operating Margin 18.7%
Oper. Margin - 3 Yr. Avg. 16.7%
Pre-Tax Margin 18%
Pre-Tax Margin - 3 Yr. Avg. 16.4%
Net Profit Margin 15.7%
Net Profit Margin - 3 Yr. Avg. 14.1%
Effective Tax Rate 12.7%
Eff/ Tax Rate - 3 Yr. Avg. 14%
Payout Ratio 0%

ICLR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ICLR stock intrinsic value calculation we used $1666 million for the last fiscal year's total revenue generated by Icon. The default revenue input number comes from 2016 income statement of Icon. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ICLR stock valuation model: a) initial revenue growth rate of 4.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ICLR is calculated based on our internal credit rating of Icon, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Icon.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ICLR stock the variable cost ratio is equal to 68.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $226 million in the base year in the intrinsic value calculation for ICLR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4% for Icon.

Corporate tax rate of 27% is the nominal tax rate for Icon. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ICLR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ICLR are equal to 12.5%.

Life of production assets of 13.7 years is the average useful life of capital assets used in Icon operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ICLR is equal to 12.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $945 million for Icon - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 54.659 million for Icon is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Icon at the current share price and the inputted number of shares is $6.3 billion.

RELATED COMPANIES Price Int.Val. Rating
INCR INC Research H 40.50 531.70  str.buy
PRAH PRA Health Sci 88.90 118.00  buy
MEDP Medpace Holdin 38.03 28.84  sell
LH Laboratory of 177.79 205.26  buy
MDSO Medidata Solut 67.98 54.73  hold
IBM International 156.18 173.04  hold

COMPANY NEWS

▶ Icon PLC beats 4Q profit forecasts   [Feb-15-18 06:20AM  Associated Press]
▶ ICON plc Value Analysis (NASDAQ:ICLR) : December 1, 2017   [Dec-01-17 10:56AM  Capital Cube]
▶ ETFs with exposure to ICON plc : November 13, 2017   [Nov-13-17 12:33PM  Capital Cube]
▶ ETFs with exposure to ICON plc : November 2, 2017   [Nov-02-17 12:15PM  Capital Cube]
▶ Icon PLC beats Street 3Q forecasts   [Oct-26-17 06:35AM  Associated Press]
▶ ICON Reports Third Quarter 2017 Results   [06:00AM  Business Wire]
▶ Stocks To Watch Ahead Of Earnings: PRA Health Sciences   [Oct-11-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to ICON plc : August 23, 2017   [Aug-23-17 04:27PM  Capital Cube]
▶ Icon PLC tops Street 2Q forecasts   [Jul-27-17 10:33PM  Associated Press]
▶ ICON Acquires Mapi Group   [06:05AM  Business Wire]
▶ ICON Reports Second Quarter 2017 Results   [06:00AM  Business Wire]
▶ Historically Strong Stocks in June   [May-31-17 01:00PM  Investopedia]
▶ Which Stocks Are Showing Rising Relative Strength?   [May-30-17 03:30PM  Investor's Business Daily]
▶ ETFs with exposure to ICON Plc : May 22, 2017   [May-22-17 01:46PM  Capital Cube]
▶ ETFs with exposure to ICON Plc : May 4, 2017   [May-04-17 04:03PM  Capital Cube]
▶ ICON Plc Value Analysis (NASDAQ:ICLR) : May 1, 2017   [May-01-17 05:02PM  Capital Cube]
▶ Icon PLC beats 1Q profit forecasts   [Apr-27-17 06:16AM  Associated Press]
▶ ICON Reports First Quarter 2017 Results   [06:00AM  Business Wire]
▶ ICON Awarded Best CRO at World Vaccine Congress 2017   [Apr-12-17 05:00AM  Business Wire]
▶ Parexel Is Discovering the Drugs of the Future   [Apr-10-17 04:44PM  TheStreet.com]
▶ ETFs with exposure to ICON Plc : April 7, 2017   [Apr-07-17 04:50PM  Capital Cube]
▶ Icon PLC meets 4Q profit forecasts   [06:34AM  Associated Press]
▶ ICON Plc Value Analysis (NASDAQ:ICLR) : January 10, 2017   [Jan-10-17 10:54AM  Capital Cube]
▶ ICON Issues Financial Guidance for Full Year 2017   [Jan-09-17 04:15PM  Business Wire]
▶ Is ICON PLC (ICLR) A Good Stock To Buy?   [Dec-14-16 02:13AM  Insider Monkey]
▶ Is ICON PLC (ICLR) A Good Stock To Buy?   [02:13AM  at Insider Monkey]
Financial statements of ICLR
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.